Cyprotex - News
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here.

Cyprotex expands further in to the United States

Cyprotex expands further in to the United States with the appointment of Global Head of Business Development


Cyprotex PLC, the drug discovery technology and information company, is pleased to announce its further expansion in to the United States. Mitchell Winfree has been appointed the senior role of Global Head of Business Development. His role is further complemented by the additional appointment of a Director of West Coast Business Development. Both will concentrate on capturing North American sales opportunities.

The US is seen to offer a great wealth of opportunities for Cyprotex in terms of key partners, collaborations and customers. With as much as 60% of the early stage global drug development concentrated in North America, an abundance of small and medium-sized biotechs / Contract Research Organisations (CRO’s) and generally greater propensity toward outsourcing services such as high-throughput ADME/Tox screening, this territory has become a principal focus.

Mitchell Winfree becomes Global Head of Business Development and brings international experience in the pharmaceutical and biotechnology industry, having held senior positions at both Absorption Systems LP, a privately held CRO working with Pharmaceuticals and Biotech partners, and PPD, Inc (DNA Sciences, Inc) an applied genetics company focused on the discovery and commercialization of DNA based diagnostic tests

Cyprotex has also appointed an experienced Director of West Coast Business Development, with a view to echoing the success of last year’s similar appointment on the East Coast.

Commenting on these appointments, Robert Morrisson Atwater, CEO of Cyprotex, said: ‘We welcome the new appointments into the Cyprotex Group. Both individuals have significant experience and innovative flair, and will play a substantial role in driving forward sales as the Company enters into an exciting phase of growth and development.”

For further information:

Cyprotex PLC
Robert Morrison Atwater,Chairman and Chief Executive Officer
Tel: +44 (0)1625 505 100
ir@cyprotex.com
www.cyprotex.com

Code Securities Limited
Chris Collins, Corporate Finance
Tel: +44 (0)20 7776 1200
cic@codesecurities.com
www.codesecurities.com

Media Enquires:
Abchurch

Heather Salmond/Georgina Bonham
Tel: +44 (0)20 7398 7700
heather.salmond@abchurch-group.com
www.abchurch-group.com


Contact us

News categories

Archives

Contact us to discuss your ADME Tox issues or request a quote

Telephone:
North America (East Coast): 888-297-7683
Europe: +44 1625 505100

 

or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.

Close